E 10 (E-10)

Subscribe to Selected New Research on E 10

97 relevant articles (1 outcomes, 7 trials/studies) found for this Bio-Agent

Description: prolongs duration of action potential

Also Known As:

E-10; N-(2-aminoethyl)-N-(2-(octylamino)ethyl)glycine monohydrochloride, mixt. with N,N-bis(2-(octylamino)ethyl)glycine monohydrochloride

Relationship Network

Bio-Agent Context: Research Results

Pharmaceutical Preparations

Drug Combinations: 850

E 10: 97

Amino Acids, Peptides, and Proteins

Amino Acids: 8786

Glycine: 2907

E 10: 97

Experts

1.	Florido, J F: 1 article (03/2005)
2.	Sáenz de San Pedro, B: 1 article (03/2005)
3.	Llanes, E: 1 article (03/2005)
4.	Lahoz, C: 1 article (03/2005)
5.	Quiralte, J: 1 article (03/2005)
6.	Villalba, M: 1 article (03/2005)
7.	Barral, P: 1 article (03/2005)
8.	Cárdaba, B: 1 article (03/2005)
9.	Arias de Saavedra, J M: 1 article (03/2005)
10.	Rodríguez, R: 1 article (03/2005)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 05/01/2003 - "Three patients were alive after 3, 5 e 10 years from the diagnosis of metastases, 2 of them are presently disease free." 09/01/1977 - "Based on vitamin B12-binding patterns, the following relatively distinct groups were defined: (A) 50% had normal results; (B) 6% had very high transcobalamin (TC) I and vitamin B12 levels as reported in isolated instances previously: most had hepatic metastases and early death, and all had definite metastatic disease; (C) 11% had high vitamin B12 levels with little or no unsaturated TC I elevation: most also had hepatic and other metastases and early death; (D) 23% had high vitamin B12-binding capacity with normal TC I and vitamin B12 levels: there were no distinguishing features for this group other than an increased proportion of black patients; and (E) 10% had low vitamin B12 levels, in many cases not associated with vitamin B12 deficiency or other known causes of low serum levels. " Order ALL the reference details at left...
2.	Hypertension (High Blood Pressure) 02/01/2001 - "Compared to the normotensive subjects, the five OHyp who developed hypertension had more pronounced alterations of LV diastolic function, that is, significantly higher mitral A (54 +/- 7 v 44 +/- 9 cm/sec, hypertensives v normotensives, P < .05), lower E/A ratio (1.31 +/- 0.14 v 1.82 +/- 0.48, P < .05), increased systolic-to-diastolic pulmonary vein flow ratio (1.11 +/- 0.3 v 0.81 +/- 0.16, P < .005), longer myocardial isovolumic relaxation time (57 +/- 7 v 46 +/- 12 msec, P < .05) as well as smaller myocardial E (10 +/- 1 v 13 +/- 2 cm/sec, P < .05) and E/A ratio (1.29 +/- 0.25 v 1.78 +/- 0.43, P < .05), despite similar LV mass (91 +/- 16 v 93 +/- 18 g/m2). " 05/15/2006 - "During transient hypertension, irrespective of forepaw stimulation, BP increases (i.e., >10 mm Hg) produced a transient increase in the blood oxygen level-dependent (BOLD) intensity resulting in a significant numbers of voxels correlating to the BP time courses (P < 0.05), and the number of these voxels increased as BP increased, becoming substantial at BP > 30 mm Hg. The activation patterns with BP increases and stimulation overlapped spatially resulting in an enhanced cerebral activation to simultaneous forepaw stimulation (P < 0.05). " 03/01/1982 - "The effects of the converting enzyme inhibitor, SQ 14,225, on the renin-angiotensin system, adrenal function and blood pressure were investigated in 14 hypertensive patients, i.e., 10 with essential hypertension (EH) and 4 with renovascular hypertension (RVH). " 03/01/2004 - "METHODS: This was a multicenter, prospective, randomized, double-blind, parallel group study, to evaluate the efficacy and tolerability of manidipine (M; 10-20 mg/day), in comparison with enalapril (E; 10-20 mg/day) in the treatment of hypertension in 136 patients with CKD secondary to primary renoparenchymal disease. " Order ALL the reference details at left...
3.	Myocardial Infarction 05/01/1999 - "The associations with myocardial infarction (i.e., 10% increase; 95% confidence interval = 3, 18) and chronic obstructive pulmonary disease (12% increase, 95% confidence interval = 6, 17) were found for the means of 3 and 4 d prior to death. " 11/01/1990 - "The effects of low-dose infusion of atrial natriuretic factor (ANF; 3 pmol/kg/min; i.e., 10 ng/kg/min) were investigated in a single-blind, random-order, placebo-controlled study of 12 patients with uncomplicated acute myocardial infarction (MI). " Order ALL the reference details at left...
4.	Gastroesophageal Reflux (GERD) 04/01/2003 - "METHODS: In the cross-over design used in the study, 9 patients with symptomatic GERD were administered a low-residue diet (i.e., 10 g fiber/day) during 2, 7-day periods, receiving either 6.6 g of FOS or placebo 3 times daily after meals. " 01/01/2006 - "Because few patients with idiopathic gastro-oesophageal reflux disease/peptic ulcer disease have been treated long-term (i.e., >10 years), there is little known to address the above areas of potential concern. " Order ALL the reference details at left...
5.	Breast Neoplasms (Breast Cancer) 01/01/1999 - "With the exception of RRR-delta-tocopherol, the tocopherols (alpha, beta, and gamma) and the acetate derivative of RRR-alpha-tocopherol (RRR-alpha-tocopheryl acetate) were ineffective in induction of apoptosis in both cell lines when tested within the range of their solubility, i.e., 10-200 micrograms/ml. In summary, these studies demonstrate that naturally occurring tocotrienols and RRR-delta-tocopherol are effective apoptotic inducers for human breast cancer cells." 03/15/1983 - "Ninety evaluable metastatic breast cancer patients refractory to hormonal therapy and combinations of cyclophosphamide, methotrexate, 5-fluorouracil, and doxorubicin were treated with a low-dose mitomycin regimen, i.e., 10 mg/m2 intravenously every 28 days. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tocotrienols
2.	Tocopherols
3.	alpha-Tocopherol
4.	Atrial Natriuretic Factor (ANF)
5.	Enalapril
6.	delta-tocopherol
7.	manidipine
8.	Immunoglobulin E (IgE)
9.	Lactic Acid
10.	Oxygen

Related Therapies and Procedures

1.	Preoperative Care
2.	Cholecystectomy
3.	Blood Transfusion (Blood Transfusions)

Best Treatments:
Research Summary Report
on Neoplasm Metastasis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3261 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>